Cite
Adaptive infusion of a glucagon‐like peptide‐1/glucagon receptor co‐agonist G3215, in adults with overweight or obesity: Results from a phase 1 randomized clinical trial.
MLA
Hope, David C. D., et al. “Adaptive Infusion of a Glucagon‐like Peptide‐1/Glucagon Receptor Co‐agonist G3215, in Adults with Overweight or Obesity: Results from a Phase 1 Randomized Clinical Trial.” Diabetes, Obesity & Metabolism, vol. 26, no. 4, Apr. 2024, pp. 1479–91. EBSCOhost, https://doi.org/10.1111/dom.15448.
APA
Hope, D. C. D., Ansari, S., Choudhury, S., Alexiadou, K., Tabbakh, Y., Ilesanmi, I., Lazarus, K., Davies, I., Jimenez, P. L., Yang, W., Ball, L., Malviya, R., Reglinska, B., Khoo, B., Minnion, J., Bloom, S. R., & Tan, T. M. ‐M. (2024). Adaptive infusion of a glucagon‐like peptide‐1/glucagon receptor co‐agonist G3215, in adults with overweight or obesity: Results from a phase 1 randomized clinical trial. Diabetes, Obesity & Metabolism, 26(4), 1479–1491. https://doi.org/10.1111/dom.15448
Chicago
Hope, David C. D., Saleem Ansari, Sirazum Choudhury, Kleopatra Alexiadou, Yasmin Tabbakh, Ibiyemi Ilesanmi, Katharine Lazarus, et al. 2024. “Adaptive Infusion of a Glucagon‐like Peptide‐1/Glucagon Receptor Co‐agonist G3215, in Adults with Overweight or Obesity: Results from a Phase 1 Randomized Clinical Trial.” Diabetes, Obesity & Metabolism 26 (4): 1479–91. doi:10.1111/dom.15448.